Alcohol Dependence clinical trials

Explore recruiting alcohol dependence clinical trials.

Recruiting alcohol dependence studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alcohol Dependence trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

ICONICplus - Randomized, double-blind, placebo-controlled trial to investigate the Effects of Cannabidiol plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrexone hydrochloride film-coated tablet, 50 mg, manufactured by Sun Pharmaceutical Industries Limited, India with NALTREXONE GH (naltrexone hydrochloride) film-coated tablets 50 mg, Product of Generic Health Pty Ltd Suite 2, Level 2 19-23 Prospect Street Box Hill, VIC, 3128, Australia, in healthy adult, human subjects under fasting condition.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Alcohol Dependence trials by city

Alcohol Dependence in Toronto Alcohol Dependence in Vancouver Alcohol Dependence in Montreal Alcohol Dependence in Calgary Alcohol Dependence in Edmonton Alcohol Dependence in Ottawa Alcohol Dependence in Winnipeg Alcohol Dependence in Quebec City Alcohol Dependence in Hamilton Alcohol Dependence in Kitchener Alcohol Dependence in London Alcohol Dependence in Halifax Alcohol Dependence in New York Alcohol Dependence in Los Angeles Alcohol Dependence in Chicago Alcohol Dependence in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease